Home | Contact | Donate | Stay Connected

News

Our Dual Lens Approach

BVGH works to solve major global health problems by finding the common ground between the needs of patients in poor countries and the pragmatic needs of companies.

Sanofi-Aventis' TB Drug Rifapentine Receives Orphan Drug Status In EU

07/08/2010

French drug maker Sanofi-Aventis SA (SNY) said Thursday that the European Commission has granted Orphan Drug status for rifapentine for the treatment of tuberculosis or TB, reports Fierce Biotech. Read more ...

Home | Contact | Site Map

To help solve the global health crisis, biopharmaceutical innovation is needed. BIO Ventures for Global Health (BVGH) works to engage companies to drive partnerships and invest in global health initiatives that result in the new drugs, vaccines, and diagnostics that will save lives in poor countries.